Europe
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA)…
Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation
1 December 2018
The proliferation of health data in our ever more digitalised world of health care creates opportunities for better research around – and delivery of – pharmaceutical…
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
This report provides a detailed summary of a panel discussion held at the HTAi 2017 annual meeting in Rome on the current approaches to MIP in…
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
1 July 2018
Using a multidisciplinary methodological approach combining a theoretical economic framework with uptake/market share analyses by country and interviews, this OHE research concludes that: (i) IP incentives…
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
1 December 2017
The centralised procedure was created in 1995 to facilitate access to innovative medicines across the European Union. Since then the scope of authorisation via the centralised…
Improving Efficiency and Resource Allocation in Future Cancer Care
9 January 2016
The economic burden that cancer poses on our society is staggering – 25 million years of healthy life lost, at cost of €126 billion including €52…
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis…
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
1 April 2011
Antimicrobial resistance (AMR) to drugs is a natural and unavoidable consequence of treating infectious diseases. A growing global public health threat, AMR reduces the chances of…
Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
1 February 2011
This paper examines the potentially positive impact of differential pricing in Europe and the overall negative effects of international reference pricing (IRP) measures. The authors point…